PT3345625T - Composição farmacêutica e sua administração - Google Patents

Composição farmacêutica e sua administração

Info

Publication number: PT3345625T
Authority: PT; Portugal
Prior art keywords: administrations; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2008-08-13

Application number

PT172041899T

Other languages

English (en)

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-13

Filing date

2009-08-13

Publication date

2021-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41206223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3345625(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-13 Application filed by Vertex Pharma filed Critical Vertex Pharma

2021-02-10 Publication of PT3345625T publication Critical patent/PT3345625T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Emergency Medicine (AREA)

PT172041899T 2008-08-13 2009-08-13 Composição farmacêutica e sua administração PT3345625T (pt)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US8870408P	2008-08-13	2008-08-13
US8880108P	2008-08-14	2008-08-14
US9009608P	2008-08-19	2008-08-19
US14616309P	2009-01-21	2009-01-21
US18152709P	2009-05-27	2009-05-27
US18334509P	2009-06-02	2009-06-02

Publications (1)

Publication Number	Publication Date
PT3345625T true PT3345625T (pt)	2021-02-10

Family

ID=41206223

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT172041899T PT3345625T (pt)	2008-08-13	2009-08-13	Composição farmacêutica e sua administração
PT97891253T PT2328618T (pt)	2008-08-13	2009-08-13	Composição farmacêutica de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolino-3-carboxamida e sua administração

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT97891253T PT2328618T (pt)	2008-08-13	2009-08-13	Composição farmacêutica de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolino-3-carboxamida e sua administração

Country Status (27)

Country	Link
US (1)	US20120220625A1 (pt)
EP (3)	EP2328618B1 (pt)
JP (2)	JP5575768B2 (pt)
KR (5)	KR20170072950A (pt)
CN (1)	CN102231990B (pt)
AU (2)	AU2009282419B2 (pt)
BR (1)	BRPI0916877A2 (pt)
CA (1)	CA2733908C (pt)
CY (2)	CY1119945T1 (pt)
DK (2)	DK2328618T3 (pt)
EA (1)	EA021706B1 (pt)
ES (2)	ES2857152T3 (pt)
HK (2)	HK1161140A1 (pt)
HR (2)	HRP20180328T1 (pt)
HU (2)	HUE035931T2 (pt)
IL (3)	IL211203A (pt)
LT (2)	LT3345625T (pt)
ME (1)	ME03019B (pt)
MX (2)	MX2011001782A (pt)
NO (1)	NO2328618T3 (pt)
NZ (1)	NZ591535A (pt)
PL (2)	PL2328618T3 (pt)
PT (2)	PT3345625T (pt)
RS (2)	RS61408B1 (pt)
SI (2)	SI3345625T1 (pt)
WO (1)	WO2010019239A2 (pt)
ZA (1)	ZA201101097B (pt)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
EP1664006A2 (en)	2003-09-06	2006-06-07	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
DK2489659T3 (en)	2004-06-24	2018-02-12	Vertex Pharma	Modulators of ATP binding cassette conveyors
KR20080053297A (ko)	2005-08-11	2008-06-12	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유종 트랜스막 전도도 조정자의 조절자
CA2627358C (en)	2005-11-08	2015-10-06	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2007087066A2 (en)	2005-12-28	2007-08-02	Vertex Pharmaceuticals Incorporated	1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
PT3091011T (pt)	2006-04-07	2018-03-07	Vertex Pharma	Moduladores de transportadores de cassete de ligação a atp
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
AU2008251504B2 (en)	2007-05-09	2013-07-18	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2009038913A2 (en)	2007-08-24	2009-03-26	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
PL2225230T3 (pl)	2007-12-07	2017-08-31	Vertex Pharmaceuticals Incorporated	Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
JP2011506331A (ja) *	2007-12-07	2011-03-03	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
PL2231606T3 (pl)	2007-12-07	2013-07-31	Vertex Pharma	Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2009108657A2 (en)	2008-02-28	2009-09-03	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
ES2442945T3 (es)	2008-03-31	2014-02-14	Vertex Pharmaceuticals Inc.	Derivados de piridilo como moduladores del CFTR
MX2011003249A (es) *	2008-09-29	2011-05-19	Vertex Pharma	Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
AR074060A1 (es)	2008-10-23	2010-12-22	Vertex Pharma	Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
SG193156A1 (en)	2009-03-20	2013-09-30	Vertex Pharma	Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK2555754T3 (en)	2010-04-07	2016-04-18	Vertex Pharma	Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
AU2011237601B2 (en)	2010-04-07	2015-08-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2608775A2 (en) *	2010-08-27	2013-07-03	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
HUE032771T2 (en)	2011-05-18	2017-10-30	Concert Pharmaceuticals Inc	Deuterated ivacaftor derivatives
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9254291B2 (en)	2011-11-08	2016-02-09	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US20130224293A1 (en) *	2012-02-27	2013-08-29	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20150065539A1 (en)	2012-04-06	2015-03-05	The Uab Research Foundation	Methods for Increasing CFTR Activity
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2875830A4 (en)	2012-07-20	2016-02-24	Otsuka Pharma Co Ltd	TABLET HAVING DRY INK FILM ON THE SURFACE THEREOF, AND INK FOR INKJET PRINTER
UA117464C2 (uk)	2012-11-02	2018-08-10	Вертекс Фармасьютікалз Інкорпорейтед	Фармацевтична композиція для лікування захворювання, опосередкованого трансмембранним регулятором провідності муковісцидозу cftr
WO2014078842A1 (en)	2012-11-19	2014-05-22	Concert Pharmaceuticals, Inc.	Deuterated cftr potentiators
BR112015023328A2 (pt)	2013-03-13	2017-07-18	Flatley Discovery Lab	compostos de piridazinona e métodos para o tratamento de fibrose cística
NZ716840A (en) *	2013-08-27	2017-06-30	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
NZ720958A (en) *	2013-11-12	2022-02-25	Vertex Pharma	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
SG11201605588YA (en) *	2014-01-09	2016-08-30	Verastem Inc	Compositions and methods for treatment of abnormal cell growth
NZ723859A (en) *	2014-03-14	2023-01-27	Servier Lab	Pharmaceutical compositions of therapeutically active compounds and their uses
LT3131582T (lt)	2014-04-15	2018-10-25	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cistinės fibrozės transmembraninio laidumo reguliatorių sukeltų ligų gydymui
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
RU2020134082A (ru)	2014-10-06	2020-11-27	Вертекс Фармасьютикалз Инкорпорейтед	Модуляторы регулятора трансмембранной проводимости при муковисцидозе
MX370450B (es) *	2014-10-07	2019-12-13	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
AU2015350049B2 (en) *	2014-11-18	2021-08-19	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
AU2016326441B2 (en)	2015-09-21	2021-11-25	Vertex Pharmaceuticals (Europe) Limited	Administration of deuterated CFTR potentiators
AU2016327603B2 (en)	2015-09-25	2021-04-22	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
WO2017177230A1 (en) *	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
FR3055800B1 (fr)	2016-09-15	2020-06-26	Unither Pharmaceuticals	Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
MX2019003620A (es)	2016-09-30	2019-08-01	Vertex Pharma	Modulador del regulador de conductancia transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador.
PT3551622T (pt)	2016-12-09	2020-11-12	Vertex Pharma	Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
BR112019025801A2 (pt)	2017-06-08	2020-07-07	Vertex Pharmaceuticals Incorporated	métodos de tratamento para fibrose cística
CA3068609A1 (en)	2017-07-01	2019-01-10	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
US11517564B2 (en)	2017-07-17	2022-12-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20200171015A1 (en)	2017-07-17	2020-06-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MX2020001302A (es)	2017-08-02	2020-03-20	Vertex Pharma	Procesos para preparar compuestos de pirrolidina.
IL273831B2 (en)	2017-10-19	2024-10-01	Vertex Pharma	Crystal forms and preparations of CFTR modulators
SG11202004264VA (en)	2017-12-01	2020-06-29	Vertex Pharma	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019113089A1 (en)	2017-12-04	2019-06-13	Vertex Pharmaceuticals Incorporated	Compositions for treating cystic fibrosis
JP7245834B2 (ja)	2017-12-08	2023-03-24	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
PL3752510T3 (pl)	2018-02-15	2023-05-08	Vertex Pharmaceuticals Incorporated	Makrocykle jako modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa, ich kompozycje farmaceutyczne, ich zastosowanie w leczeniu mukowiscydozy oraz proces ich wytwarzania
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP4218754A3 (en)	2018-11-14	2023-08-16	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
AR118555A1 (es)	2019-04-03	2021-10-20	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
WO2020242935A1 (en)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
TW202115092A (zh)	2019-08-14	2021-04-16	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
AU2020328028A1 (en)	2019-08-14	2022-03-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
US20220313698A1 (en)	2019-08-14	2022-10-06	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
AU2020408173A1 (en) *	2019-12-20	2022-06-09	Intervet International B.V.	A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix
EP4164618A4 (en) *	2020-06-10	2024-06-19	Board of Regents, The University of Texas System	3D LASER SINTERING PROCESS FOR IMPROVED ACTIVE INGREDIENT RELEASE
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
WO2022013360A1 (en)	2020-07-17	2022-01-20	Synthon B.V.	Pharmaceutical composition comprising ivacaftor
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AU2021325923A1 (en)	2020-08-13	2023-04-06	Vertex Pharmaceuticals Incorporated	Crystalline forms of CFTR modulators
EP4225750A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225765A2 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3197173A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076620A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3197857A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20240144973A (ko)	2022-02-03	2024-10-04	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 치료 방법
WO2023150236A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en)	2022-02-08	2023-08-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL315715A (en)	2022-04-06	2024-11-01	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulation
AU2023273614A1 (en)	2022-05-16	2024-11-07	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2023224924A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2024031081A1 (en)	2022-08-04	2024-02-08	Vertex Pharmaceuticals Incorporated	Compositions for the treatment of cftr-mediated diseases
EP4335434A1 (en)	2022-08-17	2024-03-13	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical compositions comprising ivacaftor
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
TW202421102A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2672549A1 (en)	2001-11-14	2003-06-12	Ben-Zion Dolitzky	Amorphous and crystalline forms of losartan potassium and process for their preparation
CN101664411A (zh) *	2003-11-14	2010-03-10	味之素株式会社	苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
JP2006206612A (ja) *	2004-05-27	2006-08-10	Ono Pharmaceut Co Ltd	固形製剤用組成物
DK3219705T3 (da) *	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
MX2009006806A (es)	2006-12-22	2009-08-27	Vertex Pharma	Secado por rocio fluidizado.
CA2742042A1 (en) *	2008-10-23	2010-04-29	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator

2009
- 2009-08-13 DK DK09789125.3T patent/DK2328618T3/en active
- 2009-08-13 JP JP2011522994A patent/JP5575768B2/ja active Active
- 2009-08-13 KR KR1020177016117A patent/KR20170072950A/ko active Application Filing
- 2009-08-13 NZ NZ591535A patent/NZ591535A/xx unknown
- 2009-08-13 DK DK17204189.9T patent/DK3345625T3/da active
- 2009-08-13 EP EP09789125.3A patent/EP2328618B1/en active Active
- 2009-08-13 ES ES17204189T patent/ES2857152T3/es active Active
- 2009-08-13 PT PT172041899T patent/PT3345625T/pt unknown
- 2009-08-13 KR KR1020197037948A patent/KR20190143497A/ko active Application Filing
- 2009-08-13 MX MX2011001782A patent/MX2011001782A/es unknown
- 2009-08-13 PT PT97891253T patent/PT2328618T/pt unknown
- 2009-08-13 ME MEP-2018-54A patent/ME03019B/me unknown
- 2009-08-13 WO PCT/US2009/004629 patent/WO2010019239A2/en active Application Filing
- 2009-08-13 KR KR1020117005734A patent/KR20110042356A/ko active Search and Examination
- 2009-08-13 ES ES09789125.3T patent/ES2660143T3/es active Active
- 2009-08-13 EP EP20211291.8A patent/EP3842037A1/en active Pending
- 2009-08-13 LT LTEP17204189.9T patent/LT3345625T/lt unknown
- 2009-08-13 EA EA201170330A patent/EA021706B1/ru unknown
- 2009-08-13 KR KR1020227014317A patent/KR20220057663A/ko not_active IP Right Cessation
- 2009-08-13 CN CN2009801354496A patent/CN102231990B/zh active Active
- 2009-08-13 RS RS20210129A patent/RS61408B1/sr unknown
- 2009-08-13 PL PL09789125T patent/PL2328618T3/pl unknown
- 2009-08-13 HU HUE09789125A patent/HUE035931T2/hu unknown
- 2009-08-13 PL PL17204189T patent/PL3345625T3/pl unknown
- 2009-08-13 BR BRPI0916877A patent/BRPI0916877A2/pt not_active Application Discontinuation
- 2009-08-13 EP EP17204189.9A patent/EP3345625B1/en active Active
- 2009-08-13 SI SI200932107T patent/SI3345625T1/sl unknown
- 2009-08-13 LT LTEP09789125.3T patent/LT2328618T/lt unknown
- 2009-08-13 MX MX2014008855A patent/MX366161B/es unknown
- 2009-08-13 CA CA2733908A patent/CA2733908C/en active Active
- 2009-08-13 KR KR1020247015082A patent/KR20240066199A/ko active Application Filing
- 2009-08-13 AU AU2009282419A patent/AU2009282419B2/en active Active
- 2009-08-13 SI SI200931803T patent/SI2328618T1/en unknown
- 2009-08-13 HU HUE17204189A patent/HUE053357T2/hu unknown
- 2009-08-13 RS RS20180161A patent/RS56894B1/sr unknown
- 2009-08-13 NO NO09789125A patent/NO2328618T3/no unknown
2011
- 2011-02-10 ZA ZA2011/01097A patent/ZA201101097B/en unknown
- 2011-02-13 IL IL211203A patent/IL211203A/en active IP Right Grant
2012
- 2012-02-10 US US13/370,540 patent/US20120220625A1/en not_active Abandoned
- 2012-02-29 HK HK12102076.9A patent/HK1161140A1/xx unknown
2014
- 2014-03-12 JP JP2014048523A patent/JP2014111656A/ja not_active Withdrawn
2016
- 2016-08-16 AU AU2016216569A patent/AU2016216569B2/en active Active
2017
- 2017-05-21 IL IL252421A patent/IL252421B/en active IP Right Grant
2018
- 2018-02-22 HR HRP20180328TT patent/HRP20180328T1/hr unknown
- 2018-02-26 CY CY20181100229T patent/CY1119945T1/el unknown
- 2018-12-11 HK HK18115889.2A patent/HK1256805A1/zh unknown
2020
- 2020-07-05 IL IL275854A patent/IL275854A/en unknown
2021
- 2021-02-05 HR HRP20210208TT patent/HRP20210208T1/hr unknown
- 2021-02-22 CY CY20211100146T patent/CY1123901T1/el unknown

Also Published As

Publication number	Publication date
IL275854A (en)	2020-08-31
RS56894B1 (sr)	2018-04-30
WO2010019239A2 (en)	2010-02-18
AU2009282419A1 (en)	2010-02-18
ME03019B (me)	2018-10-20
HRP20210208T1 (hr)	2021-03-19
HUE053357T2 (hu)	2021-06-28
SI3345625T1 (sl)	2021-04-30
NO2328618T3 (pt)	2018-04-28
EP2328618B1 (en)	2017-11-29
EP3842037A1 (en)	2021-06-30
HK1161140A1 (pt)	2012-08-24
US20120220625A1 (en)	2012-08-30
PL3345625T3 (pl)	2021-06-14
KR20170072950A (ko)	2017-06-27
ZA201101097B (en)	2012-05-30
MX2011001782A (es)	2012-02-08
JP2011530598A (ja)	2011-12-22
EP3345625B1 (en)	2020-12-09
DK2328618T3 (en)	2018-02-19
SI2328618T1 (en)	2018-04-30
AU2016216569A1 (en)	2016-09-01
KR20220057663A (ko)	2022-05-09
IL211203A (en)	2017-06-29
CA2733908A1 (en)	2010-02-18
NZ591535A (en)	2012-12-21
PL2328618T3 (pl)	2018-06-29
EA021706B1 (ru)	2015-08-31
LT2328618T (lt)	2018-03-26
AU2016216569B2 (en)	2018-01-25
IL211203A0 (en)	2011-04-28
ES2660143T3 (es)	2018-03-21
HRP20180328T1 (hr)	2018-04-20
BRPI0916877A2 (pt)	2016-02-10
HK1256805A1 (zh)	2019-10-04
PT2328618T (pt)	2018-03-05
AU2009282419B2 (en)	2016-05-19
CN102231990B (zh)	2013-09-25
CA2733908C (en)	2017-05-30
WO2010019239A3 (en)	2011-05-26
EP2328618A2 (en)	2011-06-08
DK3345625T3 (da)	2021-02-01
AU2009282419A2 (en)	2011-03-31
ES2857152T3 (es)	2021-09-28
JP5575768B2 (ja)	2014-08-20
IL252421B (en)	2020-07-30
LT3345625T (lt)	2021-02-10
MX366161B (es)	2019-07-01
HUE035931T2 (hu)	2018-06-28
IL252421A0 (en)	2017-07-31
CY1119945T1 (el)	2018-12-12
EA201170330A1 (ru)	2011-10-31
JP2014111656A (ja)	2014-06-19
KR20190143497A (ko)	2019-12-30
CY1123901T1 (el)	2022-05-27
RS61408B1 (sr)	2021-03-31
CN102231990A (zh)	2011-11-02
KR20240066199A (ko)	2024-05-14
EP3345625A1 (en)	2018-07-11
KR20110042356A (ko)	2011-04-26

Publication	Publication Date	Title
HK1256805A1 (zh)	2019-10-04	藥物組合物和其給藥
ZA201200722B (en)	2013-05-29	Pharmaceutical composition and administrations thereof
IL242883B (en)	2022-01-01	Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA201301419B (en)	2014-07-30	Pharmaceutical composition and administrations thereof
IL228817A0 (en)	2013-12-31	Pharmaceutical compounds
IL206594A (en)	2015-05-31	The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
PL2251006T3 (pl)	2017-12-29	Mikrocząstki i ich kompozycje farmaceutyczne
ZA201102715B (en)	2012-07-25	Solid pharmaceutical composition
IL208387A0 (en)	2010-12-30	Pharmaceutical composition
ZA201200079B (en)	2012-09-26	Pharmaceutical compositions and solid forms
EP2320739A4 (en)	2011-08-24	PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR STABILIZATION
ZA201100871B (en)	2012-05-30	Solid pharmaceutical composition
ZA201006224B (en)	2011-11-30	Pharmaceutical composition
GB2464200B (en)	2013-05-08	Pharmaceutical composition
HK1155062A1 (en)	2012-05-11	Pharmaceutical composition and combined agent
GB2461611B (en)	2013-02-27	Composition and use thereof
GB0817969D0 (en)	2008-11-05	Pharmaceutical composition
HK1182939A1 (en)	2013-12-13	Stable pharmaceutical composition
GB0817566D0 (en)	2008-11-05	Pharmaceutical composition
GB0817974D0 (en)	2008-11-05	Pharmaceutical composition
HU0800741D0 (en)	2009-03-02	Improved pharmaceutical composition
GB0810409D0 (en)	2008-07-09	Composition and use thereof
GB0808877D0 (en)	2008-06-25	Composition and use thereof